TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06574958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD38/CS1 injection
Description: Dosage form and specification: injection, 40mL/ dose, according to the number of positive cells 1×106/kg Properties: Colorless or slightly light white clear liquid Prescription composition: CD38/CS1 CAR T cells, 2.5% human blood albumin, 0.9% sodium chloride injection.~Administration mode: intravenous injection Storage condition: 2-8℃ for 8h Mechanism of action :38WP as a dual-target CAR T cell therapy, compared with single-target CAR T cell therapy, its advantage is that it can reduce antigen escape of tumor cells.
Study: NCT06369168

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: auricular acupuncture
Description: two auricular acupuncture methods are compared with each other and with no treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: auricular acupuncture
Description: two auricular acupuncture methods are compared with each other and with no treatment
Study: NCT06574945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous injection of propofol only
Description: Propofol was administered intravenously 2 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous injection of propofol +esketamine
Description: intravenous injection of 0.5 mg/kg ESK followed by 1.5 mg/kg of propofol or intravenous injection of 0.25 mg/kg ESK followed by 1.5 mg/kg of propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous injection of propofol +esketamine
Description: intravenous injection of 0.5 mg/kg ESK followed by 1.5 mg/kg of propofol or intravenous injection of 0.25 mg/kg ESK followed by 1.5 mg/kg of propofol
Study: NCT05007028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMONO
Description: Exposure to 1 hour of EMONO via facial mask

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical Air
Description: Exposure to 1 hour of Medical Air via facial mask
Study: NCT06240273

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn silk powder
Description: Corn silk (CS) is abundant in phenolic compounds, especially flavonoids. It also contains proteins, vitamins, carbohydrates, calcium, potassium, magnesium, sodium salts, volatile oils, sterols like sitosterol and stigmasterol, alkaloids, and saponins. Numerous studies have explored the pharmacological activities associated with CS.
Study: NCT04601519

Intervention type: OTHER
Intervention: Cross-sectional observational study
Description: Online questionnaire on the impact of type 1 diabetes on sleep quality
Study: NCT04725955

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enriched wheat bread
Description: Either 50g of glucose dissolved in 250mL water or white wheat bread or wheat bread enriched with 5mg a-cyclodextrin or wheat bread enriched with a 5mg mixture of a-cyclodextrin and encapsulated hydroxytyrosol (per 50g of available carbohydrates).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enriched wheat bread
Description: Either 50g of glucose dissolved in 250mL water or white wheat bread or wheat bread enriched with 5mg a-cyclodextrin or wheat bread enriched with a 5mg mixture of a-cyclodextrin and encapsulated hydroxytyrosol (per 50g of available carbohydrates).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched wheat bread
Description: Either 50g of glucose dissolved in 250mL water or white wheat bread or wheat bread enriched with 5mg a-cyclodextrin or wheat bread enriched with a 5mg mixture of a-cyclodextrin and encapsulated hydroxytyrosol (per 50g of available carbohydrates).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enriched wheat bread
Description: Either 50g of glucose dissolved in 250mL water or white wheat bread or wheat bread enriched with 5mg a-cyclodextrin or wheat bread enriched with a 5mg mixture of a-cyclodextrin and encapsulated hydroxytyrosol (per 50g of available carbohydrates).
Study: NCT05896033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Menthol Cigarettes
Description: Ppts will be randomly assigned to a group that receives non-menthol cigarettes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Menthol Cigarettes
Description: Ppts will be randomly assigned to a group that receives non-menthol cigarettes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Flavored E-cigarettes
Description: Ppts will be randomly assigned to a group that receives tobacco flavored e-cigarettes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Flavored E-cigarettes
Description: Ppts will be randomly assigned to a group that receives tobacco flavored e-cigarettes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menthol Cigarettes
Description: Ppts will be randomly assigned to a group that receives menthol flavored cigarettes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menthol Cigarettes
Description: Ppts will be randomly assigned to a group that receives menthol flavored cigarettes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menthol Flavored E-cigarettes
Description: Ppts will be randomly assigned to a group that receives menthol flavored e-cigarettes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menthol Flavored E-cigarettes
Description: Ppts will be randomly assigned to a group that receives menthol flavored e-cigarettes
Study: NCT04920396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E>Eye IRPL
Description: Regulated intense pulsed light therapy
Study: NCT05236686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepato-celiac lymphadenectomy
Description: Hepato-celiac lymphadenectomy in the treatment of epithelial ovarian cancer, with a maximum cytoreduction, in the circumstance of primarily diagnosed advanced epithelial ovarian cancer (primary debulking surgery or interval debulking surgery) and of platinum-sensitive recurrent ovarian cancer (no more than 4 lines of therapy).
Study: NCT05382260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to music
Description: After 5 minutes baseline, participants would listen to three kinds of music with 3 minutes washout and another 5 minutes baseline in the end, while EEG would record their cortical activity. And the order of the three kinds of music is random.

Intervention type: OTHER
Group type: OTHER
Intervention: Listening to music
Description: After 5 minutes baseline, participants would listen to three kinds of music with 3 minutes washout and another 5 minutes baseline in the end, while EEG would record their cortical activity. And the order of the three kinds of music is random.
Study: NCT06150651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Description: 1x10\^6 cells/kg CD-19 CAR-T cells
Study: NCT06083025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CleaRing
Description: The Hanita CleaRing device is an intraocular implant designed for inhibition of PCO leading to reduction in the Nd:YAG treatment rate. The device is implanted into the capsular bag after the extraction of the crystalline lens and prior to implantation of the IOL. The device is manufactured by Hanita Lenses from a hydrophilic acrylic co-polymer which is being used for the production of Intra-ocular lenses.
Study: NCT05654896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone Sodium
Description: Antibiotic will be administered prophylactically for TACE
Study: NCT04565171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yimitasvir Phosphate Capsule
Description: DAG181 100 mg (100 mg Capsule) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yimitasvir Phosphate Capsule
Description: DAG181 100 mg (100 mg Capsule) administered orally
Study: NCT04917133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity program
Description: classic 4-week rehabilitation program (standard care) + 6 APA workshops per week with collective care

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: classic 4-week rehabilitation program (standard care)
Study: NCT05367024

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Courgette soup
Description: Participants will consume one courgette soup three times a week for one 12-week intervention period as part of their normal diet.
Study: NCT04897984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liver-enriched antimicrobial peptide 2
Description: IV infusion of LEAP2, 2 hours
Study: NCT05950334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT522
Description: FT522 drug product is administered as an intravenous infusion on Days 1, 4 and 8 of a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT522
Description: FT522 drug product is administered as an intravenous infusion on Days 1, 4 and 8 of a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as an IV infusion on Day -4 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as an IV infusion on Day -4 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an IV infusion at a dose of 500 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an IV infusion at a dose of 30 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered as an IV infusion at a dose of 90 mg/m\^2 on Day -5 and Day -4 of the treatment cycle. Bendamustine may be administered as an alternative to cyclophosphamide/fludarabine.
Study: NCT06056375

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reclaiming Nature Intervention
Description: The purpose of the community intervention is to prevent health disparities in Black, Latinx, Pilipinx, and Pacific Islander communities of San Francisco, California.
Study: NCT06579820

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: tubular bandage
Description: The experimental group consisted of the group in which a tubular bandage was applied over the PIC, which was routinely applied.
Study: NCT06579482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aesculus hippocastanum, and associations
Description: combination product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aesculus hippocastanum, and associations
Description: combination product
Study: NCT06393101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRC-002
Description: BRC-002 is a non-scheduled cannabidiolic (CBD) formulation (\<.3% THC). The cannabinoids in BRC-002 are naturally biosynthesized within the Cannabis sativa L. plant as acidic forms of CBD (cannabidiolic acid; CBDA), THC (tetrahydrocannabinolic acid; THCA) and other minor cannabinoids.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BRC-002 Placebo
Description: Oral solution of mono-, di-, and triglycerides
Study: NCT05902962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-001
Description: Phase 1 open-label, single arm dose escalation study of VP-001 in participants with genetically confirmed PRPF31 mutation-associated retinal dystrophy
Study: NCT05646121

Intervention type: DEVICE
Intervention: Suprasorb® A + Ag wound dressing and rope
Description: Suprasorb® A + Ag Antimicrobial Calcium Alginate Wound Dressings / Packing Rope are soft, conformable wound coverings with a high mannuronic acid content (mass per unit area ≥100 g/m2). The silver impregnated calcium alginate fibres react with wound exudate or blood to form a gel which creates a moist wound environment. The silver contained in the wound dressing has broad antimicrobial activity, including against MRSA and VRE. Antimicrobial action (\>3 log steps) associated with the ionic silver from the silver alginate fibres (1.5%) is observed in vitro after just 24 h and this remains stable for up to seven days

Intervention type: DEVICE
Intervention: Suprasorb® A + Ag wound dressing and rope
Description: Suprasorb® A + Ag Antimicrobial Calcium Alginate Wound Dressings / Packing Rope are soft, conformable wound coverings with a high mannuronic acid content (mass per unit area ≥100 g/m2). The silver impregnated calcium alginate fibres react with wound exudate or blood to form a gel which creates a moist wound environment. The silver contained in the wound dressing has broad antimicrobial activity, including against MRSA and VRE. Antimicrobial action (\>3 log steps) associated with the ionic silver from the silver alginate fibres (1.5%) is observed in vitro after just 24 h and this remains stable for up to seven days
Study: NCT06157307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic compression
Description: Aortic compression with four different methods on each participants
Study: NCT06460974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress ball
Description: A stress ball was applied to the patients in the during chemotherapy treatment.
Study: NCT06380465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The water extract of Biang variety purple sweet potato
Description: Purple sweet potato extract is a mixture of water and Biang variety of purple sweet potato puree, enhanced with a touch of flavoring

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: The water extract of Biang variety purple sweet potato
Description: Purple sweet potato extract is a mixture of water and Biang variety of purple sweet potato puree, enhanced with a touch of flavoring
Study: NCT04406948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCND00EP1
Description: Patients will take cannabis oil during the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will take carrier oil during the study

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: A standard 12-lead ECG will be recorded using digital ECG recording equipment provided to the investigational site. The ECG has to be performed prior to laboratory samplings at time points indicated in the Schedule of Assessments.~The ECG recording will be reviewed by investigator and case of need consultation with cardiologist will be performed. The investigator has the final decision on the clinical significance of the ECG results.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: ECG
Description: A standard 12-lead ECG will be recorded using digital ECG recording equipment provided to the investigational site. The ECG has to be performed prior to laboratory samplings at time points indicated in the Schedule of Assessments.~The ECG recording will be reviewed by investigator and case of need consultation with cardiologist will be performed. The investigator has the final decision on the clinical significance of the ECG results.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EEG
Description: An EEG is an electrophysiological monitoring method that records the electrical activity and measures voltage fluctuations resulting from ionic current within the neurons of the brain. In clinical contexts, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time.
Study: NCT04920396

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warm compress
Description: Fabric mask with anti-bacterial coating filled with BodyBeads® heated in a microwave for 30 seconds before application over the eyes for 5 minutes
Study: NCT04406948

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: EEG
Description: An EEG is an electrophysiological monitoring method that records the electrical activity and measures voltage fluctuations resulting from ionic current within the neurons of the brain. In clinical contexts, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood and urine collection
Description: safety blood tests - hematology\\blood count and biochemistry standard blood tests urinalysis - urine test analysis

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Blood and urine collection
Description: safety blood tests - hematology\\blood count and biochemistry standard blood tests urinalysis - urine test analysis
Study: NCT05707468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT combined with abiraterone
Description: The patients will receive long-term ADT combined with abiraterone.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant hormone and RT
Description: The patients will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.
Study: NCT05617690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclopol
Description: Cyclopol 0.4mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. Anesthesia maintenance strategy is cyclopol 0.8-2.4 mg/kg/h and remifentanil 0.15 - 0.2 μg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 1-3mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. The anesthesia maintenance strategy is propofol 4-8mg/kg/h and remifentanil 0.15 - 0.2 μ g/kg/h
Study: NCT06185257

Intervention type: DEVICE
Intervention: EEG
Description: Methodology Subjects selected are divided into 3 groups A. Patient with chronic kidney disease under dialysis B. Patients with nephrotic syndrome~* Patients in remission~* Patients relapse C. Normal control group~Detailed history including age, sex , residence ,complain, renal symptoms will be taken.~Detailed examination, lab investigations, and treatment will be recorded~Imaging ( EEG) , results of the three groups will be assessed and compared and lab investigation ( lipid profile of all patients) will be measured

Intervention type: DEVICE
Intervention: EEG
Description: Methodology Subjects selected are divided into 3 groups A. Patient with chronic kidney disease under dialysis B. Patients with nephrotic syndrome~* Patients in remission~* Patients relapse C. Normal control group~Detailed history including age, sex , residence ,complain, renal symptoms will be taken.~Detailed examination, lab investigations, and treatment will be recorded~Imaging ( EEG) , results of the three groups will be assessed and compared and lab investigation ( lipid profile of all patients) will be measured

Intervention type: DEVICE
Intervention: EEG
Description: Methodology Subjects selected are divided into 3 groups A. Patient with chronic kidney disease under dialysis B. Patients with nephrotic syndrome~* Patients in remission~* Patients relapse C. Normal control group~Detailed history including age, sex , residence ,complain, renal symptoms will be taken.~Detailed examination, lab investigations, and treatment will be recorded~Imaging ( EEG) , results of the three groups will be assessed and compared and lab investigation ( lipid profile of all patients) will be measured
Study: NCT05807243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention for healthy weight loss
Description: Balanced and varied dietary plan adjusted to each participant's needs, with an approximate reduction of 500 Kcal from their total metabolic expenditure. The diet will be followed by the subjects during the 4 weeks of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention for healthy weight loss
Description: Balanced and varied dietary plan adjusted to each participant's needs, with an approximate reduction of 500 Kcal from their total metabolic expenditure. The diet will be followed by the subjects during the 4 weeks of the study.
Study: NCT05404477

Intervention type: DEVICE
Group type: OTHER
Intervention: TransAeris System
Description: The TransAeris System includes four TransLoc® intramuscular diaphragm electrodes, the TransAeris external stimulator, and the FrictionLoc® connectors which provide the interface between the TransLoc electrodes and the TransAeris stimulator.

Intervention type: DEVICE
Group type: OTHER
Intervention: TransAeris System
Description: The TransAeris System includes four TransLoc® intramuscular diaphragm electrodes, the TransAeris external stimulator, and the FrictionLoc® connectors which provide the interface between the TransLoc electrodes and the TransAeris stimulator.
Study: NCT06685211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyetronic rtACS
Description: The repetitive, transorbital alternating current stimulation (rtACS) is a device for non-invasive Interventional Neurophysiology. The electrical charge and current density applied during rtACS safe and able to modulate existing neuronal elements in the eye and brain.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rtACS
Description: Participants will wear the Eyetronic system but there will be no active stimulations applied.
Study: NCT06684249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve Block Injections
Description: This intervention involves the administration of supratrochlear and greater occipital nerve block injections. The injections consist of a mixture of local anesthetics and corticosteroids, designed to reduce the frequency and severity of migraine episodes. The procedure will be repeated every 12 weeks for a total duration of 6 months to assess the long-term efficacy and safety in managing chronic migraine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A
Description: Participants in this arm will receive Botulinum toxin A injections as per the PREEMPT protocol tailored for chronic migraine treatment. The treatment involves multiple injections around the head and neck regions, administered every 12 weeks over a 6-month period. This standard approach aims to reduce migraine frequency through neuromodulation of pain pathways.